
EPRX Stock Forecast & Price Target
EPRX Analyst Ratings
Bulls say
Eupraxia Pharmaceuticals is a promising investment opportunity due to their innovative Diffusphere technology for optimized drug delivery, promising clinical development programs in the treatment of EoE and chronic OA knee pain, and their experienced leadership team, including their new Chief Medical Officer with a focus on osteoarthritis. Market pricing reflects high probability of success, however, key questions remain around dosing and commercial rollout. Risks include clinical development, regulatory, and commercial risks, as well as potential financing and global supply chain challenges given their Canadian origins. Overall, the company shows strong potential for success in the market, but further data is needed to confirm their hypotheses.
Bears say
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company with a negative outlook primarily due to concerns about the ability to deliver their drug EP-104GI below strictures and the limited sample size of their current clinical data. Furthermore, while their ongoing Phase 2b study may help clarify their competitive profile and potential revenue opportunity, their valuation is based on a probability-weighted DCF model with only a 70% chance of success and a risk-adjusted sales estimate of $257M in 2031.
This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares